Pacira | PCRX - Sales Revenues


Pacira reported $196.87M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Assertio Holdings USD 29.2M 1.92M Sep/2024
Astellas Pharma JPY 537.93B 33.28B Mar/2026
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Ironwood Pharmaceuticals USD 47.71M 74.35M Dec/2025
J&J USD 24.1B 500M Mar/2026
Ligand Pharmaceuticals USD 59.66M 55.8M Dec/2025
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Novo Nordisk DKK 79.14B 4.16B Dec/2025
Pacira USD 196.87M 17.35M Dec/2025
Perrigo USD 1.11B 70M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Supernus Pharmaceuticals USD 211.6M 19.5M Dec/2025
Teva Pharmaceutical Industries USD 14.63B 10M Dec/2025
Xeris Pharmaceuticals USD 85.81M 11.43M Dec/2025
Xoma USD 25K 5M Sep/2024
Zoetis USD 2.4B 0 Dec/2025